DBV Technologies reports positive results of Viaskin Peanut study
Category: #health  By Mateen Dalal  Date: 2020-01-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

DBV Technologies reports positive results of Viaskin Peanut study

 

  • The biopharmaceutical firm reported positive results from the PEOPLE Phase-3 study of Viaskin Peanut in the children suffering from the peanut allergy.
  • Patients produced long-term and durable clinical benefits with an additional two years of treatment.
  • The reported treatment represents the largest long-term peanut allergy immunotherapy trial devised till date.

France headquartered leading biopharmaceutical firm, DBV Technologies has reportedly announced formulating positive topline results of the long time running PEOPLE Phase-3 study of Viaskin Peanut in the children suffering from the allergies of peanuts. It has been reported that the study has been conducted for the children belonging to the ages 4 to 11 years and those allergic to peanut consumption.

For the uninitiated, PEOPLE study is a continuous study meant for evaluating the long-term safety, efficiency, and the tolerability of the peanut allergy treatment, Viaskin Peanut 250 microgram in the patients who have had completed the Phase-3 PEPITES trial.

As per reliable sources, the results showcase long-term clinical benefits as demonstrated by an increase in the eliciting dose (ED), which reduce the chances of reacting to unintentional peanut exposure. Furthermore, the study revealed that over 75.9 per cent of the patients had improved their ED from the standard point whilst nearly 51.8 per cent had reached an ED of minimum 1000 milligram peanut protein by the end of the study.

Speaking of the accomplishment, the Principal Investigator of PEPITES and PEOPLE, and the Director of Allergy and Immunology Center and Section Head at Children’s Hospital, Colorado, Dr. David Fleischer quoted that the new data has aided the overall clinical benefit of Viaskin Peanut. The firm is extremely pleased to obtain the positive results of the trial carried in the patients.

It was reported that nearly three out of the four patients displayed an increase in the ED. He further added that these data also provide a testament to the fact that the treatment might as well reduce the risk of reaction from the accidental exposure. This could be carried out by increasing the threshold reactivity via an option which is optimally safe and convenient.
 

Source credit: https://www.dbv-technologies.com/wp-content/uploads/2020/01/dbv-technologies-reports-positive-three-year-long-term-data-from-the-people-phase-iii-open-label-extension-study-of-viaskin-peanut-in-children-with-peanut-allergy.pdf

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
By Mateen Dalal

Air France–KLM S.A., one of the leading global air transport players, has reportedly made a proposal to invest in Malaysia Airlines and gain around 49 percent stake. Japan Airlines (JAL) is also looking to acquire a 25 percent stake in Mal...

Accenture opens innovation center in South Beach Road office
Accenture opens innovation center in South Beach Road office
By Mateen Dalal

Accenture, an Irish multinational professional services company, has recently opened a global innovation center within the Accenture’s office at South Beach Road, which is supported by EDB (Economic Development Board) in Singapore. It will pro...

Verrica unveils positive data from VP-102 study in molluscum treatment
Verrica unveils positive data from VP-102 study in molluscum treatment
By Mateen Dalal

Findings from the study are being produced at the 17th Annual Winter Clinical Dermatology Conference in Kohala Coast The data indicated a considerable increase in the percentage of patients with lesion clearance in VP-102 group Verrica Pharmaceu...